zoledronic acid has been researched along with Intertrochanteric Fractures in 63 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (28.57) | 29.6817 |
| 2010's | 31 (49.21) | 24.3611 |
| 2020's | 14 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Black, DM; Cauley, JA; Ewing, SK; Kim, TY; Nakamura, T; Napoli, N; Reid, IR; Schafer, AL; Shiraki, M; Takeuchi, Y | 1 |
| Du, D; Gu, M; Jin, L; Xu, J; Yang, Z; Zhang, C; Zhao, S; Zhao, T; Zhao, W; Zheng, L | 1 |
| Abe, S; Kamatani, T; Kashii, M; Koizumi, K; Kuriyama, K; Mizuno, N; Yamamoto, K; Yoshida, A; Yoshikawa, H | 1 |
| Arnaud, M; Bioteau, C; Blain, H; Boudissa, M; Drevet, S; Gavazzi, G; Jalbert, R; Parent, T; Tonetti, J | 1 |
| Chang, CW; Hsu, JC; Hwang, JS; Li, CC; Tai, TW; Wu, CH | 1 |
| Hu, L; Li, YF; Luo, C; Qin, SX; Qu, XL; Sheng, ZF; Wan, XM; Wang, QY; Wang, XB; Yue, C | 1 |
| Jiang, XY; Li, XP; Wu, XB; Yang, MH; Zhang, P; Zhu, SW | 1 |
| Gates, M; Hartling, L; Nuspl, M; Pillay, J; Vandermeer, B; Wingert, A | 1 |
| Bonel, H; Everts-Graber, J; Gahl, B; Häuselmann, H; Lehmann, D; Lehmann, T; Reichenbach, S; Studer, U; Ziswiler, HR | 1 |
| Ahern, E; Black, AJ; Dockery, F; Gregson, CL; Javaid, MK; Johansen, A; MacLullich, AMJ; Sahota, O | 1 |
| Kumar, A; Qayoom, I; Teotia, AK | 1 |
| Evangelatos, G; Fragoulis, GE; Iliopoulos, A | 1 |
| Bauer, DC; Black, DM; Colon-Emeric, CS; Cummings, SR; Lyles, KW; Pieper, CF | 1 |
| Chalatsis, GI; Karachalios, T; Koutalos, AA; Malizos, KN; Varsanis, G | 1 |
| Albert, SG; Reddy, S | 1 |
| Irie, C; Ito, M; Nakamura, T; Ota, Y; Shiraki, M; Sone, T; Tanaka, S | 1 |
| Bersabe, D; Graybill, S; Kaufman, N; Kuiper, BW; Tate, JM | 1 |
| Ha, YC; Kim, TY; Koo, KH; Lee, YK | 1 |
| Brasure, M; Butler, M; Ensrud, KE; Fink, HA; Forte, ML; MacDonald, R; Nelson, VA; Olson, CM; Rosebush, CE; Schousboe, JT; Taylor, BC; Ullman, K; Wilt, TJ | 1 |
| Li, CW; Liang, BC; Liu, K; Liu, Z; Mao, YF; Shi, XL; Wu, LG | 1 |
| Camacho-Alonso, F; López-Jornet, P; Vicente-Hernández, A | 1 |
| Arden, NK; Cooper, C; Javaid, MK; Judge, A; Lyles, KW; Prieto-Alhambra, D | 1 |
| Anitua, E; Begoña, L; Cobos, R; Orive, G; Serrano, AJ | 1 |
| Adachi, JD; Boonen, S; Bucci-Rechtweg, C; Colón-Emeric, CS; Johnson, R; Lyles, KW; Magaziner, JS; Mesenbrink, P; Nordsletten, L; Orwig, DL; Pieper, CF; Recknor, C; Su, G | 1 |
| Bouvet, A; Caruba, T; Pouchot, J; Sabatier, B; Savoldelli, V | 1 |
| Aktaş, İ; Çincin, A; Doğan Metin, F; Erdoğan, O; İlgezdi, ZD; Kepez, A; Kıvrak, T; Şilte, AD; Ünlü Özkan, F; Yılmaz Kaysın, M | 1 |
| Reid, IR | 1 |
| He, Q; Li, Q; Li, Y; Liu, L; Pei, FX; Wang, DL; Zhao, WB | 1 |
| Blanco, R; Sánchez, A | 1 |
| Hagino, H; Moriwaki, K; Mouri, M | 1 |
| Deeks, ED; Perry, CM | 1 |
| Adachi, JD; Boonen, S; Colón-Emeric, CS; Eriksen, EF; Hu, H; Hyldstrup, L; Lavecchia, C; Lyles, KW; Magaziner, JS; Mesenbrink, P; Nordsletten, L; Pieper, CF; Recknor, C | 1 |
| Demontiero, O; Duque, G | 1 |
| Adami, S; Black, DM; Boonen, S; Cauley, JA; Cummings, SR; Delmas, PD; Eastell, R; Felsenberg, D; Lippuner, K; Mesenbrink, P; Palermo, L | 1 |
| Boonen, S; Colón-Emeric, CS; Delmas, P; Eriksen, EF; Lyles, KW; Magaziner, J; Mesenbrink, P; Pieper, CF | 1 |
| Abrahamsen, B; Eiken, PA | 1 |
| Bauer, DC; Black, DM; Boonen, S; Bucci-Rechtweg, C; Cauley, J; de Papp, A; Eastell, R; Genant, HK; Kelly, MP; Leung, PC; Palermo, L; Santora, A | 1 |
| Shane, E | 1 |
| Dell, RM; Ott, SM; Silverman, SL | 1 |
| Pozzi, S; Raje, N | 1 |
| Bouler, JM; Bujoli, B; Despas, C; Fayon, F; Gauthier, O; Janvier, P; Khairoun, I; Massiot, D; Mellier, C; Montavon, G; Rouillon, T; Schnitzler, V; Walcarius, A | 1 |
| Chen, JF; Chen, PQ; Chin, LS; Hwang, JS; Leung, PC; Tsai, KS; Yang, TS | 1 |
| Cameron, ID; Chen, JS; Cumming, RG; March, LM; Sambrook, PN; Seibel, MJ; Simpson, JM | 1 |
| Adachi, J; Boonen, S; Bucci-Rechtweg, C; Colón-Emeric, C; Haentjens, P; Hyldstrup, L; Lyles, KW; Magaziner, J; Major, N; Mesenbrink, P; Nordsletten, L; Olson, S; Recknor, C | 1 |
| Adachi, JD; Boonen, S; Bucci-Rechtweg, C; Colón-Emeric, CS; Eriksen, EF; Hyldstrup, L; Lyles, KW; Magaziner, JS; Mautalen, C; Moore, KA; Nordsletten, L; Pieper, CF; Recknor, C; Su, G | 1 |
| Adachi, JD; Boonen, S; Bucci-Rechtweg, CM; Colón-Emeric, CS; Haentjens, P; Lyles, KW; Magaziner, JS; Pieper, CF; Su, G | 1 |
| Ishiguro, N; Iwase, T; Kishimoto, Y; Koyama, A; Masui, T; Matsuo, H; Yoshida, G | 1 |
| Adachi, JD; Boonen, S; Bucci-Rechtweg, C; Claessens, F; Colón-Emeric, CS; Haentjens, P; Kaufman, JM; Lyles, KW; Magaziner, J; Milisen, K; Orwoll, E; Rizzoli, R; Sermon, A; Su, G; Vanderschueren, D; Witvrouw, R | 1 |
| Black, DM; Eastell, R; Sycheva, AV; Yang, L | 1 |
| Bigos, ST | 1 |
| Adachi, J; Caminis, J; Colón-Emeric, CS; Horowitz, ZD; Janning, C; Lyles, KW; Magaziner, J; Mesenbrink, P; Pieper, CF; Rosario-Jansen, T; Suh, TT | 1 |
| Black, DM; Boonen, S; Caminis, J; Cauley, JA; Cosman, F; Cummings, SR; Delmas, PD; Eastell, R; Eriksen, EF; Hu, H; Hue, TF; Krasnow, J; Lakatos, P; Leung, PC; Man, Z; Mautalen, C; Mesenbrink, P; Reid, IR; Rosario-Jansen, T; Sellmeyer, D; Tong, K | 1 |
| Geusens, PP; Lems, WF | 1 |
| Abrams, K; Adachi, JD; Boonen, S; Colón-Emeric, CS; Eriksen, EF; Hodgson, PK; Horowitz, Z; Hyldstrup, L; Lavecchia, C; Lyles, KW; Magaziner, JS; Mautalen, C; Mesenbrink, P; Moore, KA; Nordsletten, L; Orloff, JJ; Pieper, CF; Recknor, C; Zhang, J | 1 |
| Calis, KA; Pucino, F | 1 |
| Casas, N; Delmas, PD; Eriksen, EF; Grbic, JT; Hua, Y; Landesberg, R; Leung, PC; Lin, SQ; Mesenbrink, P; Recknor, CP; Reid, IR | 1 |
| Betchyk, K; Caminis, J; Colon-Emeric, C; Heaney, RR; Janning, C; LeBoff, MS; Lyles, KW; Pieper, CF; Shostak, J; Zhang, J | 1 |
| van den Berg, P | 1 |
| Al-Khalidi, H; Karam, R; Steinbuch, M | 1 |
| Lopez, CA; Tasneem, Z | 1 |
| Altundag, K; Bulut, N; Sari, E | 1 |
9 review(s) available for zoledronic acid and Intertrochanteric Fractures
| Article | Year |
|---|---|
Effect of bisphosphonate on hip fracture in patients with osteoporosis or osteopenia according to age: a meta-analysis and systematic review.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Hip Fractures; Humans; Middle Aged; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid | 2022 |
Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
Topics: Adult; Alendronate; Canada; Denosumab; Diphosphonates; Female; Hip Fractures; Humans; Male; Middle Aged; Osteoporotic Fractures; Primary Health Care; Primary Prevention; Risedronic Acid; Systematic Reviews as Topic; Zoledronic Acid | 2023 |
CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.
Topics: Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Denosumab; Diphosphonates; Drug Costs; Female; Hip Fractures; Humans; Imidazoles; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Teriparatide; Zoledronic Acid | 2017 |
Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Drug Administration Schedule; Duration of Therapy; Female; Hip Fractures; Humans; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Spinal Fractures; Zoledronic Acid | 2019 |
Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Hip Fractures; Humans; Imidazoles; Middle Aged; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Spinal Fractures; Zoledronic Acid | 2013 |
Zoledronic acid: a review of its use in the treatment of osteoporosis.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Hip Fractures; Humans; Imidazoles; Male; Osteoporosis; Osteoporosis, Postmenopausal; Zoledronic Acid | 2008 |
Annual zoledronic acid for osteoporosis.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Drug Costs; Female; Hip Fractures; Humans; Imidazoles; Infusions, Intravenous; Osteoporosis, Postmenopausal; Postoperative Care; Randomized Controlled Trials as Topic; Zoledronic Acid | 2008 |
Once-yearly zoledronic acid in hip fracture prevention.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Hip Fractures; Humans; Imidazoles; Middle Aged; Zoledronic Acid | 2009 |
Selected therapy-related clinical research topics in osteoporosis.
Topics: Bone Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Hip Fractures; Humans; Hypercalcemia; Imidazoles; Injections; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Osteoporosis; Zoledronic Acid | 2003 |
21 trial(s) available for zoledronic acid and Intertrochanteric Fractures
| Article | Year |
|---|---|
The Interaction of Acute-Phase Reaction and Efficacy for Osteoporosis After Zoledronic Acid: HORIZON Pivotal Fracture Trial.
Topics: Acute-Phase Reaction; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Hip Fractures; Humans; Imidazoles; Osteoporosis; Zoledronic Acid | 2022 |
Call to action: a five nations consensus on the use of intravenous zoledronate after hip fracture.
Topics: Bone Density Conservation Agents; Consensus; Hip Fractures; Humans; Ireland; Osteoporotic Fractures; Zoledronic Acid | 2023 |
The effect of once-yearly zoledronic acid on hip structural and biomechanical properties derived using computed tomography (CT) in Japanese women with osteoporosis.
Topics: Aged; Aged, 80 and over; Asian People; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Hip Fractures; Humans; Imidazoles; Osteoporosis; Placebo Effect; Tomography, X-Ray Computed; Zoledronic Acid | 2018 |
Study on Zoledronic Acid Reducing Acute Bone Loss and Fracture Rates in Elderly Postoperative Patients with Intertrochanteric Fractures.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Drug Administration Schedule; Female; Follow-Up Studies; Fracture Fixation, Intramedullary; Hip Fractures; Humans; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Postoperative Care; Recurrence; Secondary Prevention; Treatment Outcome; Zoledronic Acid | 2019 |
Fracture prevention in patients with cognitive impairment presenting with a hip fracture: secondary analysis of data from the HORIZON Recurrent Fracture Trial.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Cognition Disorders; Diphosphonates; Double-Blind Method; Female; Follow-Up Studies; Hip Fractures; Humans; Imidazoles; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Psychiatric Status Rating Scales; Secondary Prevention; Treatment Outcome; Zoledronic Acid | 2014 |
Subgroup variations in bone mineral density response to zoledronic acid after hip fracture.
Topics: Aged; Aged, 80 and over; Body Mass Index; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Female; Follow-Up Studies; Hip Fractures; Humans; Imidazoles; Male; Middle Aged; Sex Factors; Zoledronic Acid | 2014 |
Treatment of osteoporotic intertrochanteric fractures by zoledronic acid injection combined with proximal femoral nail anti-rotation.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Nails; Combined Modality Therapy; Diphosphonates; Female; Hip Fractures; Humans; Imidazoles; Injections; Male; Middle Aged; Osteoporotic Fractures; Quality of Life; Zoledronic Acid | 2016 |
Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Female; Follow-Up Studies; Hip Fractures; Humans; Imidazoles; Male; Middle Aged; Osteoporosis, Postmenopausal; Risk Factors; Spinal Fractures; Time Factors; Zoledronic Acid | 2009 |
Potential mediators of the mortality reduction with zoledronic acid after hip fracture.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Cause of Death; Diphosphonates; Female; Hip Fractures; Humans; Imidazoles; Incidence; Male; Middle Aged; Placebos; Risk Factors; United States; Zoledronic Acid | 2010 |
The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Asian People; Bone Density; Bone Density Conservation Agents; China; Demography; Diphosphonates; Female; Femoral Neck Fractures; Hip Fractures; Humans; Imidazoles; Incidence; Injections, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Zoledronic Acid | 2011 |
Association between timing of zoledronic acid infusion and hip fracture healing.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Fracture Healing; Fractures, Ununited; Hip Fractures; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Osteoporotic Fractures; Postoperative Care; Postoperative Period; Radiography; Risk Factors; Zoledronic Acid | 2011 |
Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON-Recurrent Fracture Trial.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Female; Fractures, Bone; Health Status; Hip Fractures; Humans; Imidazoles; Male; Middle Aged; Quality of Life; Spinal Fractures; Surveys and Questionnaires; Zoledronic Acid | 2011 |
Clinical risk factors for recurrent fracture after hip fracture: a prospective study.
Topics: Age Factors; Aged; Aged, 80 and over; Body Mass Index; Bone Density Conservation Agents; Calcium; Dietary Supplements; Diphosphonates; Female; Hip Fractures; Humans; Imidazoles; Male; Prospective Studies; Risk Factors; Secondary Prevention; Sex Factors; Treatment Outcome; Vitamin D; Zoledronic Acid | 2011 |
Once-yearly zoledronic acid in older men compared with women with recent hip fracture.
Topics: Absorptiometry, Photon; Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Hip Fractures; Humans; Imidazoles; Incidence; Injections, Intravenous; Male; Osteoporosis; Prevalence; Time Factors; Treatment Outcome; Zoledronic Acid | 2011 |
Site-specific differential effects of once-yearly zoledronic acid on the hip assessed with quantitative computed tomography: results from the HORIZON Pivotal Fracture Trial.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Follow-Up Studies; Hip Fractures; Hip Joint; Humans; Imidazoles; Middle Aged; Observer Variation; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Tomography, X-Ray Computed; Zoledronic Acid | 2013 |
The HORIZON Recurrent Fracture Trial: design of a clinical trial in the prevention of subsequent fractures after low trauma hip fracture repair.
Topics: Bone Density; Calcium; Developed Countries; Diphosphonates; Female; Hip Fractures; Humans; Imidazoles; Male; Middle Aged; Placebos; Randomized Controlled Trials as Topic; Vitamin D; Zoledronic Acid | 2004 |
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Biomarkers; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Fractures, Bone; Hip Fractures; Humans; Imidazoles; Incidence; Infusions, Intravenous; Osteoporosis, Postmenopausal; Risk; Spinal Fractures; Zoledronic Acid | 2007 |
[Fracture prevention in postmenopausal women with osteoporosis by an annual infusion of zoledronic acid].
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Female; Fractures, Bone; Hip Fractures; Humans; Imidazoles; Infusions, Intravenous; Osteoporosis, Postmenopausal; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2007 |
Zoledronic acid and clinical fractures and mortality after hip fracture.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Calcium; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Fractures, Bone; Hip Fractures; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Survival Analysis; Vitamin D; Zoledronic Acid | 2007 |
Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Epidemiologic Methods; Female; Hip Fractures; Humans; Imidazoles; Jaw Diseases; Middle Aged; Osteitis; Osteomyelitis; Osteonecrosis; Osteoporosis, Postmenopausal; Periapical Abscess; Zoledronic Acid | 2008 |
Distribution and correlates of serum 25-hydroxyvitamin D levels in a sample of patients with hip fracture.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Calcium; Cross-Sectional Studies; Diphosphonates; Double-Blind Method; Female; Femur Neck; Hip Fractures; Humans; Imidazoles; Logistic Models; Male; Multivariate Analysis; Sex Factors; Tissue Distribution; Vitamin D; Zoledronic Acid | 2007 |
33 other study(ies) available for zoledronic acid and Intertrochanteric Fractures
| Article | Year |
|---|---|
Tolerability of the first infusion of once-yearly zoledronic acid within one to two weeks after hip fracture surgery.
Topics: Aged, 80 and over; Antipyretics; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Hip Fractures; Humans; Hypocalcemia; Imidazoles; Male; Osteoporosis; Vitamin D; Zoledronic Acid | 2022 |
Zoledronic Acid Contraindications Prevalence among Hip-Fractured Patients Aged 75 Years or Over Hospitalized in an Orthogeriatric Unit.
Topics: Aged; Aged, 80 and over; Creatinine; Female; Hip Fractures; Hospitalization; Humans; Hypocalcemia; Prevalence; Retrospective Studies; Zoledronic Acid | 2022 |
The Impact of Various Anti-Osteoporosis Drugs on All-Cause Mortality After Hip Fractures: A Nationwide Population Study.
Topics: Bone Density Conservation Agents; Cohort Studies; Denosumab; Diphosphonates; Hip Fractures; Humans; Osteoporosis; Osteoporotic Fractures; Zoledronic Acid | 2022 |
Cost-effectiveness analysis of five drugs for treating postmenopausal women in the United States with osteoporosis and a very high fracture risk.
Topics: Bone Density Conservation Agents; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Denosumab; Female; Hip Fractures; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Postmenopause; Teriparatide; United States; Zoledronic Acid | 2023 |
All-cause mortality risk in older patients with femoral neck fracture.
Topics: Aged; Aged, 80 and over; Female; Femoral Fractures; Femoral Neck Fractures; Femur Neck; Hip Fractures; Humans; Male; Prospective Studies; Risk Factors; Zoledronic Acid | 2022 |
Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denosumab; Diphosphonates; Female; Hip Fractures; Humans; Ibandronic Acid; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Registries; Spinal Fractures; Zoledronic Acid | 2023 |
Nanohydroxyapatite Based Ceramic Carrier Promotes Bone Formation in a Femoral Neck Canal Defect in Osteoporotic Rats.
Topics: Animals; Bone Density Conservation Agents; Bone Morphogenetic Protein 2; Bone Regeneration; Bone Resorption; Calcium Sulfate; Drug Carriers; Exosomes; Female; Femur Neck; Hip Fractures; Hydroxyapatites; Nanostructures; Osteogenesis; Osteoporosis; Rats, Sprague-Dawley; Recombinant Proteins; Transforming Growth Factor beta; X-Ray Microtomography; Zoledronic Acid | 2020 |
Zoledronic acid in nine patients with transient osteoporosis of the hip.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Female; Hip Fractures; Humans; Infusions, Intravenous; Magnetic Resonance Imaging; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Zoledronic Acid | 2020 |
Zoledronic acid reduces the rate of clinical fractures after surgical repair of a hip fracture regardless of the Pretreatment bone mineral density.
Topics: Bone Density; Bone Density Conservation Agents; Femur Neck; Hip Fractures; Humans; Zoledronic Acid | 2021 |
The effect of zoledronic acid and high-dose vitamin D on function after hip fractures. A prospective cohort study.
Topics: Hip Fractures; Humans; Prospective Studies; Vitamin D; Vitamins; Zoledronic Acid | 2022 |
After the fall: improving osteoporosis treatment following hip fracture.
Topics: Accidental Falls; Aged; Bone Density Conservation Agents; Denosumab; Drug Administration Schedule; Hip Fractures; Hospitalization; Humans; Osteoporosis; Osteoporotic Fractures; Quality Improvement; Retrospective Studies; Secondary Prevention; Standard of Care; Texas; Zoledronic Acid | 2018 |
To withhold or to implement bisphosphonate after cementless hip arthroplasty: a dilemma in elderly hip fracture patients.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Bone Density Conservation Agents; Diphosphonates; Female; Hip Fractures; Hip Prosthesis; Humans; Male; Osteoporosis; Retrospective Studies; Withholding Treatment; Zoledronic Acid | 2019 |
Short-term effect of zoledronic acid upon fracture resistance of the mandibular condyle and femoral head in an animal model.
Topics: Animals; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Femur Head; Hip Fractures; Imidazoles; Male; Mandibular Condyle; Mandibular Fractures; Rats; Rats, Sprague-Dawley; Time Factors; Zoledronic Acid | 2013 |
Evaluation of the prescription of osteoporosis treatment after a major osteoporotic fracture.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Calcium; Dietary Supplements; Diphosphonates; Female; Follow-Up Studies; Fractures, Bone; France; Hip Fractures; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Prescriptions; Raloxifene Hydrochloride; Retrospective Studies; Thiophenes; Treatment Outcome; Vitamin D; Wrist Injuries; Zoledronic Acid | 2014 |
Acute effect of zoledronic acid infusion on atrial fibrillation development in patients with osteoporosis.
Topics: Atrial Fibrillation; Diphosphonates; Echocardiography; Electrocardiography, Ambulatory; Female; Hip Fractures; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Zoledronic Acid | 2015 |
Efficacy, effectiveness and side effects of medications used to prevent fractures.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium Compounds; Denosumab; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Hip Fractures; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Risedronic Acid; Risk Assessment; Spinal Fractures; Teriparatide; Thiophenes; Treatment Outcome; Vitamin D; Zoledronic Acid | 2015 |
Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates.
Topics: Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Drug Therapy, Combination; Female; Fractures, Spontaneous; Hip Fractures; Humans; Imidazoles; Osteoporosis, Postmenopausal; Radiography; Zoledronic Acid | 2017 |
Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Diphosphonates; Drug Administration Schedule; Drug Costs; Female; Health Care Costs; Hip Fractures; Humans; Imidazoles; Injections, Intravenous; Japan; Models, Econometric; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Quality-Adjusted Life Years; Sensitivity and Specificity; Spinal Fractures; Zoledronic Acid | 2017 |
Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density.
Topics: Aged; Aged, 80 and over; Body Mass Index; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Female; Femur Neck; Hip Fractures; Humans; Imidazoles; Spinal Fractures; Zoledronic Acid | 2009 |
[Assessment and treatment of osteoporotic hip fractures].
Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Spontaneous; Hip Fractures; Humans; Imidazoles; Life Style; Middle Aged; Osteoporosis; Practice Patterns, Physicians'; Risk Factors; Surveys and Questionnaires; Zoledronic Acid | 2010 |
Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.
Topics: Alendronate; Bone Density Conservation Agents; Confidence Intervals; Diphosphonates; Female; Femoral Fractures; Hip Fractures; Humans; Imidazoles; Osteoporosis; Randomized Controlled Trials as Topic; Zoledronic Acid | 2010 |
Evolving data about subtrochanteric fractures and bisphosphonates.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Femoral Fractures; Hip Fractures; Humans; Imidazoles; Osteoporosis; Zoledronic Acid | 2010 |
Bisphosphonates and atypical femoral fractures.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Hip Fractures; Humans; Imidazoles; Incidence; Time Factors; Zoledronic Acid | 2010 |
Bisphosphonates and atypical femoral fractures.
Topics: Alendronate; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Femoral Fractures; Hip Fractures; Humans; Imidazoles; Osteonecrosis; Risk Factors; Zoledronic Acid | 2010 |
Investigation of alendronate-doped apatitic cements as a potential technology for the prevention of osteoporotic hip fractures: critical influence of the drug introduction mode on the in vitro cement properties.
Topics: Adsorption; Alendronate; Apatites; Bone Cements; Calcium Phosphates; Dielectric Spectroscopy; Diphosphonates; Hip Fractures; Imidazoles; Magnetic Resonance Spectroscopy; Osteoporotic Fractures; Time Factors; Zoledronic Acid | 2011 |
Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study.
Topics: Aged; Aged, 80 and over; Australia; Bone Density Conservation Agents; Diphosphonates; Female; Follow-Up Studies; Frail Elderly; Hip Fractures; Homes for the Aged; Humans; Imidazoles; Male; Nursing Homes; Prospective Studies; Risk Factors; Zoledronic Acid | 2011 |
Subtrochanteric fracture in a patient receiving zoledronic acid therapy for metastatic breast cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fractures, Stress; Hip Fractures; Humans; Imidazoles; Middle Aged; Zoledronic Acid | 2011 |
Zoledronic acid and secondary prevention of fractures.
Topics: Bone Density Conservation Agents; Diphosphonates; Ethics, Research; Fractures, Bone; Hip Fractures; Humans; Imidazoles; Research Design; Zoledronic Acid | 2007 |
New annual osteoporosis drug reduces risk of death, future fractures. Infused dose is more convenient for patients, enhances overall quality of life.
Topics: Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Hip Fractures; Humans; Imidazoles; Life Style; Osteoporosis; Zoledronic Acid | 2007 |
Zoledronate, fractures, and mortality after hip fracture.
Topics: Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Hip Fractures; Humans; Imidazoles; Research Design; Risk; Zoledronic Acid | 2008 |
Zoledronate, fractures, and mortality after hip fracture.
Topics: Bone Density Conservation Agents; Data Interpretation, Statistical; Diphosphonates; Fractures, Bone; Hip Fractures; Humans; Imidazoles; Research Design; Zoledronic Acid | 2008 |
Zoledronate, fractures, and mortality after hip fracture.
Topics: Atrial Fibrillation; Bone Density Conservation Agents; Confounding Factors, Epidemiologic; Diphosphonates; Fractures, Bone; Hip Fractures; Humans; Imidazoles; Zoledronic Acid | 2008 |
Osteonecrosis of the jaw.
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Hip Fractures; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Osteoporosis, Postmenopausal; Pamidronate; Time Factors; Zoledronic Acid | 2008 |